These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 4063734)

  • 1. Exfoliative cytology after transurethral resection of superficial bladder tumours.
    Müller F; Kraft R; Zingg E
    Br J Urol; 1985 Oct; 57(5):530-4. PubMed ID: 4063734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Urinary cytology studied during 10 days after transurethral resection of bladder tumour and its relation to tumour recurrence].
    Iguchi A; Yoshinaga H; Masaki Z; Tsugitomi H; Wakayama K
    Nihon Hinyokika Gakkai Zasshi; 1991 Sep; 82(9):1430-5. PubMed ID: 1942702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative bladder washing cytology after transurethral resection. Can it predict the recurrence of urothelial carcinoma?
    Iczkowski KA; Katz G; Cascione CJ
    Acta Cytol; 2004; 48(3):380-4. PubMed ID: 15192954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Value of exfoliative cytology of the urinary bladder in occult bladder cancer and in the control of treated cancers].
    Schmitz A; Meyer U; Kierfeld G; Küchemann K
    Urologe A; 1984 Sep; 23(5):278-80. PubMed ID: 6542269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Can the persistence rate of transurethrally resected bladder tumors be lowered by postoperative instillation of silver nitrate?].
    Flamm J; Grof F
    Z Urol Nephrol; 1984 Jan; 77(1):1-6. PubMed ID: 6702326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The value of differentiated transurethral resection in primary superficial bladder cancer].
    Flamm J; Steiner R
    Urologe A; 1991 Mar; 30(2):111-3. PubMed ID: 2058065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Carcinosarcoma of the urinary bladder].
    Kuntz RM; Geyer V; Savvas V; Grosse G
    Urologe A; 1993 Jan; 32(1):59-63. PubMed ID: 8447047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer.
    Jancke G; Damm O; Rosell J; Jahnson S
    Scand J Urol Nephrol; 2008; 42(5):417-21. PubMed ID: 18609266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the management of bladder perforation during transurethral resection of superficial bladder tumors predispose to extravesical tumor recurrence?
    Skolarikos A; Chrisofos M; Ferakis N; Papatsoris A; Dellis A; Deliveliotis C
    J Urol; 2005 Jun; 173(6):1908-11. PubMed ID: 15879773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.
    Zietman AL; Grocela J; Zehr E; Kaufman DS; Young RH; Althausen AF; Heney NM; Shipley WU
    Urology; 2001 Sep; 58(3):380-5. PubMed ID: 11549485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of ultrasonography and urinary cytology in diagnosing recurrence of superficial urinary bladder cancer compared to cystoscopy.
    Roy MK; Islam MF; Kibria SA
    Bangladesh Med Res Counc Bull; 2001 Apr; 27(1):23-32. PubMed ID: 11692897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring endoscopic treatment of superficial bladder carcinoma by postoperative urinary cytology.
    Badalament RA; Gay H; Cibas ES; Herr HW; Whitmore WF; Fair WR; Melamed MR
    J Urol; 1987 Oct; 138(4):760-2. PubMed ID: 3656527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Significance of local tumor associated infiltration of mononuclear leukocytes for persistent tumor formations following transurethral resection (TUR) of bladder cancers].
    Flamm J
    Z Urol Nephrol; 1985 Feb; 78(2):65-70. PubMed ID: 3993242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy and follow-up of bladder cancer].
    Meyer D; Schmid HP; Engeler DS
    Wien Med Wochenschr; 2007; 157(7-8):162-9. PubMed ID: 17492413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of valrubicin for the chemoresection of superficial bladder cancer -- a marker lesion study.
    Newling DW; Hetherington J; Sundaram SK; Robinson MR; Kisbenedek L
    Eur Urol; 2001 Jun; 39(6):643-7. PubMed ID: 11464052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the safety and efficacy of conventional monopolar and 2-micron laser transurethral resection in the management of multiple nonmuscle-invasive bladder cancer.
    Liu H; Wu J; Xue S; Zhang Q; Ruan Y; Sun X; Xia S
    J Int Med Res; 2013 Aug; 41(4):984-92. PubMed ID: 23760914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review.
    Cumberbatch MGK; Foerster B; Catto JWF; Kamat AM; Kassouf W; Jubber I; Shariat SF; Sylvester RJ; Gontero P
    Eur Urol; 2018 Jun; 73(6):925-933. PubMed ID: 29523366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
    BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.
    Solsona E; Iborra I; Ricos JV; Monros JL; Rubio J; Almenar S
    J Urol; 2002 May; 167(5):2007-11. PubMed ID: 11956428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.